PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

BACKGROUND: The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for patients with intermediate- and poor-risk metastatic r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Buckley, Hannah L., Collinson, Fiona J., Ainsworth, Gemma, Poad, Heather, Flanagan, Louise, Katona, Eszter, Howard, Helen C., Murden, Geraldine, Banks, Rosamonde E., Brown, Joanne, Velikova, Galina, Waddell, Tom, Fife, Kate, Nathan, Paul D., Larkin, James, Powles, Thomas, Brown, Sarah R., Vasudev, Naveen S.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854710/
https://ncbi.nlm.nih.gov/pubmed/31727024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6273-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars